High frequency of antiphospholipid antibodies in relapse of multiple sclerosis: a possible indicator of inflammatory–thrombotic processes

Tatiana Koudriavtseva; Giovanna D’Agosto; Chiara Mandoj; Isabella Sperduti; Paola Cordiali-Fei

doi:10.1007/s10072-014-1823-4

High frequency of antiphospholipid antibodies in relapse of multiple sclerosis: a possible indicator of inflammatory–thrombotic processes

Tatiana Koudriavtseva, Giovanna D’Agosto, Chiara Mandoj, Isabella Sperduti, Paola Cordiali-Fei

Research output: Contribution to journal › Article › peer-review

Abstract

The exact prevalence and pathogenic role of antiphospholipid antibodies (aPL) in multiple sclerosis (MS) remain unclear. This observational laboratory-blinded study evaluated the rate of aPL positivity in healthy controls and MS patients in different disease phases to recognize their frequency and possible pathogenic meaning. Reactivity for anti-cardiolipin, anti-β2 glycoprotein I, anti-prothrombin, anti-annexin V (IgG and IgM) was studied by enzyme immunoassays in 60 healthy controls and 100 consecutive MS patients [58 relapsing–remitting (RR) patients in remission, 26 RR patients in relapse, and 16 secondary progressive patients]. The overall rate of positivity for at least one aPL was significantly higher in MS patients compared to controls (32 % vs. 7 %, respectively, p

Original language	English
Pages (from-to)	1737-1741
Number of pages	5
Journal	Neurological Sciences
Volume	35
Issue number	11
DOIs	https://doi.org/10.1007/s10072-014-1823-4
Publication status	Published - 2014

Keywords

Antiphospholipid antibodies
Beta 2-glycoprotein-I
Multiple Sclerosis
Prothrombin
Relapse

ASJC Scopus subject areas

Clinical Neurology
Psychiatry and Mental health
Dermatology

Access to Document

10.1007/s10072-014-1823-4

Cite this

@article{83dbcaa9caeb47deb1f528b081761553,

title = "High frequency of antiphospholipid antibodies in relapse of multiple sclerosis: a possible indicator of inflammatory–thrombotic processes",

abstract = "The exact prevalence and pathogenic role of antiphospholipid antibodies (aPL) in multiple sclerosis (MS) remain unclear. This observational laboratory-blinded study evaluated the rate of aPL positivity in healthy controls and MS patients in different disease phases to recognize their frequency and possible pathogenic meaning. Reactivity for anti-cardiolipin, anti-β2 glycoprotein I, anti-prothrombin, anti-annexin V (IgG and IgM) was studied by enzyme immunoassays in 60 healthy controls and 100 consecutive MS patients [58 relapsing–remitting (RR) patients in remission, 26 RR patients in relapse, and 16 secondary progressive patients]. The overall rate of positivity for at least one aPL was significantly higher in MS patients compared to controls (32 % vs. 7 %, respectively, p ",

keywords = "Antiphospholipid antibodies, Beta 2-glycoprotein-I, Multiple Sclerosis, Prothrombin, Relapse",

author = "Tatiana Koudriavtseva and Giovanna D{\textquoteright}Agosto and Chiara Mandoj and Isabella Sperduti and Paola Cordiali-Fei",

year = "2014",

doi = "10.1007/s10072-014-1823-4",

language = "English",

volume = "35",

pages = "1737--1741",

journal = "Neurological Sciences",

issn = "1590-1874",

publisher = "Springer-Verlag Italia s.r.l.",

number = "11",

}

TY - JOUR

T1 - High frequency of antiphospholipid antibodies in relapse of multiple sclerosis

T2 - a possible indicator of inflammatory–thrombotic processes

AU - Koudriavtseva, Tatiana

AU - D’Agosto, Giovanna

AU - Mandoj, Chiara

AU - Sperduti, Isabella

AU - Cordiali-Fei, Paola

PY - 2014

Y1 - 2014

N2 - The exact prevalence and pathogenic role of antiphospholipid antibodies (aPL) in multiple sclerosis (MS) remain unclear. This observational laboratory-blinded study evaluated the rate of aPL positivity in healthy controls and MS patients in different disease phases to recognize their frequency and possible pathogenic meaning. Reactivity for anti-cardiolipin, anti-β2 glycoprotein I, anti-prothrombin, anti-annexin V (IgG and IgM) was studied by enzyme immunoassays in 60 healthy controls and 100 consecutive MS patients [58 relapsing–remitting (RR) patients in remission, 26 RR patients in relapse, and 16 secondary progressive patients]. The overall rate of positivity for at least one aPL was significantly higher in MS patients compared to controls (32 % vs. 7 %, respectively, p

AB - The exact prevalence and pathogenic role of antiphospholipid antibodies (aPL) in multiple sclerosis (MS) remain unclear. This observational laboratory-blinded study evaluated the rate of aPL positivity in healthy controls and MS patients in different disease phases to recognize their frequency and possible pathogenic meaning. Reactivity for anti-cardiolipin, anti-β2 glycoprotein I, anti-prothrombin, anti-annexin V (IgG and IgM) was studied by enzyme immunoassays in 60 healthy controls and 100 consecutive MS patients [58 relapsing–remitting (RR) patients in remission, 26 RR patients in relapse, and 16 secondary progressive patients]. The overall rate of positivity for at least one aPL was significantly higher in MS patients compared to controls (32 % vs. 7 %, respectively, p

KW - Antiphospholipid antibodies

KW - Beta 2-glycoprotein-I

KW - Multiple Sclerosis

KW - Prothrombin

KW - Relapse

UR - http://www.scopus.com/inward/record.url?scp=84939871590&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939871590&partnerID=8YFLogxK

U2 - 10.1007/s10072-014-1823-4

DO - 10.1007/s10072-014-1823-4

M3 - Article

C2 - 24847961

AN - SCOPUS:84939871590

VL - 35

SP - 1737

EP - 1741

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

IS - 11

ER -

High frequency of antiphospholipid antibodies in relapse of multiple sclerosis: a possible indicator of inflammatory–thrombotic processes

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this